STAT3 and steatosis: Therapeutically, the study provides proof of concept for STAT3 inhibition (TTI-101) as being effective to ameliorate steatosis, inflammation, and fibrosis in DKO mice, confirming STAT3 as a druggable master regulator downstream of BRUCE/PTEN in murine MASH models.